The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Vizient forecasts a 3.84% rise in pharmacy spending for health systems and ambulatory surgery centers, driven by specialty and personalized medicines.

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...